Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
Authors:
Open Access
- 12 July 2013
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (10) , 2484-2492
Abstract
Neoadjuvant therapy is increasingly becoming a valid treatment option for patients with locally advanced pancreatic cancer (LAPC). In borderline resectable disease, neoadjuvant therapy is employed to improve the probability of margin-clear resections. In non-metastatic, non-resectable pancreatic cancer, treatment primarily aims to induce disease control, but may achieve conversion to surgical resectability in some patients. Several treatment modalities including chemotherapy, chemoradiotherapy (CRT) or the sequential use of both have been investigated in numerous, mostly small and non-randomized studies. Nevertheless, there is a consistent finding that neoadjuvant therapy can induce resectability in up to 30%–40% of LAPC patients. Once resection has been achieved, overall survival appears to be comparable to that observed for primarily resectable patients. Thus, patient selection evolves as an important aspect of neoadjuvant therapy; retrospective analyses identified induction chemotherapy as an appropriate tool to define LAPC patients who may benefit most from subsequent treatment with CRT. The clinical importance of induction chemotherapy may further increase once highly active protocols such as the FOLFIRINOX or the gemcitabine plus nab-paclitaxel regimen are introduced into novel multimodality treatment concepts.Keywords
This publication has 39 references indexed in Scilit:
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial DesignAnnals of Surgical Oncology, 2013
- Borderline resectable pancreatic cancer: rationale for multidisciplinary treatmentJournal of Hepato-Biliary-Pancreatic Sciences, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus StatementAnnals of Surgical Oncology, 2009
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of DiseaseJournal of the American College of Surgeons, 2008
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004